Apomorphine SL (Ixenset) (apo SL) is a dopamine receptor agonist that can enhance sexual function in patients with erectile dysfunction (ED). For a patient, the ability to achieve a physiological erection, tolerability, efficacy and the speed of onset of the therapy are of considerable importance when considering ED treatment. Recent studies have focused on determining the patient's tolerability to apo SL as a therapy for ED. In addition, the cardiovascular profile of those patients that would be likely to receive apo SL in the clinic has been assessed. These studies have shown that apo SL is safe and effective in the treatment of ED and offers a new therapeutic option for the first-line treatment of patients with different concomitant diseases including cardiovascular disease and diabetes. The most frequently reported adverse events were nausea and dizziness, but no major adverse events have been noted in any of the clinical trials.
Introduction
Erectile dysfunction (ED) is a symptom of many underlying conditions, and some of the known risk factors for this disease include diabetes mellitus, hypogonadism in association with a number of endocrinologic conditions, hypertension, vascular disease, high levels of blood cholesterol, low levels of high-density lipoprotein, drugs, neurogenic disorders, depression, alcohol ingestion and many chronic diseases. 1 Age and smoking are associated with many of these risk factors, and are, therefore, considered to be an indirect risk factor for ED. Apomorphine SL (Ixenset) (apo SL) is a dopamine receptor agonist drug with significant potential for sexual enhancement and for the treatment of ED. This review focuses on recent studies that have demonstrated the safety and patient tolerability of apo SL as an ED therapy. In particular, the cardiovascular safety profile of apo SL in the typical patient population for this therapy is discussed.
Tolerability
The four main issues of importance to patients with ED are achieving a physiological erection, tolerability, efficacy and the speed of onset of the therapy. The tolerability of an ED therapy is very important to both the physician and the patient, particularly in view of the non-life-threatening nature of ED. The tolerability of apo SL has been investigated in several studies of heterosexual men with ED; however, this paper will review three recent trials, focussing on a dose-optimisation Phase III study, 2 a forced-dose-escalation European study 3 and a double-blind crossover comparison of apo SL 3 mg with placebo and with apo SL 4 mg. 4 The dose-optimisation Phase III study determined the efficacy and safety of apo SL in 849 heterosexual men with ED. 2 Inclusion criteria for the study included adult males in a heterosexual relationship for at least 6 months if at least 50% of their attempts at intercourse failed. Patients with concomitant organic diseases such as hypertension, diabetes, coronary artery disease (CAD) and benign prostatic hyperplasia (BPH) could participate if their condition was controlled (ie typical ED patients). The study began with a 2-week screening period which involved a complete physical evaluation including medical and sexual histories, assessment of vital signs, ECG and laboratory tests. The International Index of Erectile Function 15 (IIEF-15) was used to determine the baseline severity of ED in the patients. 5 Dosing was initiated at 2 mg for the first week and was increased at the end of each of the following 2 weeks to 3 or 4 mg (higher than the recommended dose of 2 and 3 mg) depending upon patient requirements and at the discretion of the investigator.
The mean percentage of attempts resulting in erections firm enough for intercourse in this study was 39.4%, compared to 13.1% at baseline and attempts resulting in intercourse was 38.3% compared to 12.7% at baseline in patients taking their optimal dose of apo SL. 2 Average median time to erection was 23 min, and the average median duration of erection was 13 min. Most patients optimised their dose to 4 mg, suggesting that the tolerability profile of apo SL is enhanced when the dose-optimisation regimen is followed, irrespective of the cause of ED.
In the forced-dose-escalation European clinical study, the tolerability of apo SL was evaluated in 507 heterosexual men with ED. 3 Medical and psychosexual histories, physical examinations including vital signs and ECGs were taken regularly during the study, as were baseline Brief Sexual Function Inventory (BSFI) and IIEF-15 inventories. Following a 1-to 2-week screening period, patients were randomised to either placebo or apo SL on an increasing dose regimen, from 2 to 3 or 4 mg, for 8 weeks. Only 4.7% of the patients taking apo SL and 1.6% of the patients taking placebo withdrew as a result of study drug-related adverse events. Dizziness, headache, abdominal pain and hyperaesthesia were seen in both treatment groups. Overall, 87% of the patients taking apo SL completed the study, thus demonstrating that apo SL was well tolerated. The results of these two studies suggest that patients should, therefore, be requested to start with the 2 mg dose and then titrate up to the 3 mg dose for sexual intercourse, once the body has adapted to the lower dose.
In the double-blind crossover comparison of apo SL 3 mg with placebo and with apo SL 4 mg in male ED patients, 3 and 4 mg were shown to be clinically similar in terms of efficacy. 4 However, a comparison of the incidence of nausea with an erection firm enough for intercourse demonstrated that the 3 mg dose offered an improved benefit/risk profile compared to the 4 mg doses (Figure 1 ).
Safety profile
Several clinical trials have demonstrated the safety of apo SL in ED patients, with adverse events usually being mild to moderate. [2] [3] [4] 6, 7 The most commonly reported adverse events are nausea, headache and dizziness. In the dose-optimisation Phase III study treatment-related adverse events were reported by 29.4% of patients, of these 69.6% were mild, 27.2% were moderate and 3.2% were severe ( Figure 2 ).
2 Nausea was dose related and diminished with continued dosing. In the forceddose-escalation European study, treatment-related adverse events were reported by 37.8% of the patients treated with apo SL and 24.5% reported adverse events with placebo. 3 Discontinuation of apo SL is rarely due to adverse events. Nausea, when present, is often mild and transient, therefore discontinuations due to nausea are rare. Another adverse event seen with apo SL is a transient vasovagal syncope. 2, 4 However, this is very rare particularly when patients follow the doseoptimisation regimen. Furthermore, it has been shown that the adverse event rate improves with subsequent administrations. 2, 6, 7 In the double-blind crossover comparison of apo SL 3 mg with placebo and with apo SL 4 mg in male ED patients the drug was well tolerated in most patients and a good safety profile was seen. 4 Treatment-related adverse events were reported more frequently by patients receiving the 4-mg dose than those receiving either 2-or 3-mg dose. 4 Adverse events at 2 and 3 mg are substantially less frequent than the incidence with higher doses, while maintaining clinical efficacy. 6 
Cardiovascular safety
ED is often accompanied by or may be the result of concomitant diseases including hypertension, CAD, Tolerability and safety of apo SL F Montorsi S8 diabetes and BPH. 3 Therefore, the associated medicines for these disorders may be given alongside ED therapies. Apo SL has been demonstrated to be tolerated in a wide range of patients with ED, who have such concomitant diseases. In the forced-doseescalation European study, 62.6% of patients in the apo SL group were taking concomitant medications for their underlying medical condition. This is considered to be representative of the typical patient population for ED. There was no correlation made between adverse events and underlying medical conditions in this study.
Successful ED treatment for those patients with cardiovascular disorders may pose a particular risk. An increase in physical activity resulting from improved erections must be supported by the patients overall general condition and so caution must be observed in this group. In addition to the physical well being of cardiovascular patients, there is also the potential for drug-drug interactions. The safety and pharmacodynamic effects of apo SL, 5 mg tablets, were evaluated in cardiovascular patients on stable therapeutic doses of angiotensin-converting enzyme (ACE) inhibitors, b-blockers, diuretics, calcium channel blockers, a 1 -blockers or short-or long-acting nitrates. 8 The dose of apo SL used was greater than the recommended dose of 2 or 3 mg. Patients were subjected to repetitive orthostatic stress (changes from supine to standing position), which, in addition to the 5 mg dose of apo SL represents the 'worst case' evaluation of potential interactions. In patients receiving short-acting nitrates, no additional significant change in supine or standing blood pressure (BP) was observed during the 2 h following administration of apo SL compared to the placebo. However, in patients receiving longacting nitrates, there was a small drop in standing BP which was not observed in the supine BP measurements in the apo SL group compared to the placebo group (Figure 3 ). Other changes in standing BP were noticed in patients given apo SL and receiving b-blockers, diuretics, calcium channel blockers and a 1 -blockers although none of these reductions were considered serious they may point to orthostatic hypotension in some patients.
Conclusion
More than 5000 patients have been enrolled in apo SL clinical trials and they have received in excess of 120 000 doses. 9 The clinical trials discussed in this review have shown that the approved doses of apo SL, 2 and 3 mg, are safe and well tolerated in heterosexual men with ED. The patient demographics in these clinical trials mirrored the typical ED population. Apo SL offers a new therapeutic option for the first-line treatment of patients with concomitant diseases including cardiovascular disease and diabetes. Apo SL has a good safety profile, even in patients taking short-acting nitrates although patients on some other hypertensive medications should be observed carefully for possible hypotension. While the most frequently reported adverse events are nausea and dizziness, on the whole, no major adverse events have been noted in clinical studies. Apo SL, 2 and 3 mg, is therefore, a well-tolerated therapy for ED and is an appropriate first choice in a wide range of ED patients. .
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